Prognostic value of plasma brain‐derived phosphorylated Tau
Alzheimer's & Dementia · 2026-11 · 22 (11)
DOI: 10.1002/alz.71983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 13.11.2026. Verfasst von Valentina Ghisays und 17 weiteren Autor:innen. Beteiligte Einrichtung: Banner Alzheimer's Institute, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: tau Proteins, Alzheimer Disease, Brain. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
INTRODUCTION Plasma brain‐derived phosphorylated Tau217 (BD‐pTau217) may provide a more Alzheimer's disease (AD) ‐specific plasma tau measure than total pTau217, but its prognostic value is unclear. METHODS We compared baseline plasma NULISAseq biomarkers for amyloid positron emission tomography (PET) progression (positivity: Centiloid ≥ 24.1; n = 175) and clinical progression to mild cognitive impairment or AD dementia (n = 508) in cognitively unimpaired Alzheimer's Disease Neuroimaging Initiative (ADNI) participants using Cox models and time‐dependent areas under the curve (tdAUCs). RESULTS Over a median clinical follow‐up of 6 years (interquartile range [IQR], 3.0–7.3), BD‐pTau217 and total pTau217 had similar discrimination (full‐follow‐up AUC = 0.66 each; high‐versus‐low hazard ratios [HRs]; 95% confidence interval [CIs]: 2.8 [1.89–4.06] and 2.9 [1.96–4.35], respectively). Among initially amyloid‐negative participants, BD‐pTau217 better predicted progression to amyloid PET positivity at 2.5 years (tdAUC 0.82 vs. 0.69; HR = 10.54 [95% CI 2.3–48.1], p = 0.00015) and 4 years (tdAUC 0.77 vs. 0.64; HR = 7.03 [95% CI 1.9–25.6], p = 0.00055) compared to total pTau217. CONCLUSION BD‐pTau217 better predicted near‐term progression to amyloid PET positivity than total pTau217, but showed no advantage for clinical progression, supporting its potential value as an early marker of AD pathological change.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Banner Alzheimer's Institute, Phoenix, Arizona, USA.
- Banner Sun Health Research Institute, Sun City, Arizona, USA.
- Translational Genomics Research Institute, Phoenix, Arizona, USA.
- University of California San Francisco, San Francisco, California, USA.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Ghisays, V., Denkinger, M. N., Singh, A., Marques, T. M., Malek-Ahmadi, M., Jensen, K. V., Protas, H. D., Sohankar, J., Goradia, D. D., Devadas, V., Chen, Y., Li, S., Langbaum, J. B., Weiner, M. W., Reiman, E. M., Su, Y., Ashton, N. J., & Alzheimer's Disease Neuroimaging Initiative (2026). Prognostic value of plasma brain‐derived phosphorylated Tau. Alzheimer's & Dementia, 22(11). https://doi.org/10.1002/alz.71983
Vancouver
Ghisays V, Denkinger MN, Singh A, Marques TM, Malek-Ahmadi M, Jensen KV, et al. Prognostic value of plasma brain‐derived phosphorylated Tau. Alzheimer's & Dementia. 2026;22(11). doi:10.1002/alz.71983
BibTeX
@article{Ghisays2026,
author = {Ghisays, Valentina and Denkinger, Marisa N and Singh, Alpana and Marques, Tainá M and Malek-Ahmadi, Michael and Jensen, Kendall Van-Keuren and Protas, Hillary D and Sohankar, Javad and Goradia, Dhruman D and Devadas, Vivek and Chen, Yinghua and Li, Shan and Langbaum, Jessica B and Weiner, Michael W and Reiman, Eric M and Su, Yi and Ashton, Nicholas J and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
title = {Prognostic value of plasma brain‐derived phosphorylated Tau},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {11},
doi = {10.1002/alz.71983}
}
EUVIMED